Sacroiliac (SI) Joint Fusion Simplified
Management
Led by an experienced team of business and medical professionals, SI-BONE is uniquely positioned to make a dramatic impact on the
treatment options available for patients suffering from chronic unresolved low back pain.
Jeffrey Dunn, President and CEO
Mr. Dunn has over thirty years of executive experience, including service as the CEO of six companies. His medical device experience includes
sacroiliac fusion, ankle replacement, and small bone extremity fusion. Mr. Dunn has taken one company public, sold all the others to larger public
companies, served on numerous boards of directors and is an advisor to other CEOs. Prior to SI-BONE, Inc. Mr. Dunn was CEO of INBONE Technologies,
which he built into a leading ankle replacement and small bone fusion medical device company. Mr. Dunn led the sale of INBONE to Wright Medical in
April, 2008.
Prior to INBONE, Mr. Dunn was the CEO of Active Decisions. Brought in to effect a turnaround, he closed down a major product line and redirected the technology to the "software as a service" model. Active Decisions was bought by Knova Software, a public company that was subsequently sold to Consona, a private equity firm.
Previously, Mr. Dunn was the CEO of Velogic, an Internet performance testing software company. At Velogic, Mr. Dunn reinvented and expanded the product line, restructured the management team and created industry partnerships, one of which ultimately led to the acquisition of the company by Keynote Systems.
Prior to Velogic, Mr. Dunn was the CEO of EnterpriseLink, a provider of enterprise Internet enablement software. Mr. Dunn was recruited to lead a turnaround by the investors. Mr. Dunn reinvigorated the company and successfully sold the company for a substantial gain in less than one year.
Mr. Dunn was also the CEO of AccelGraphics, a 3D graphics systems supplier. Mr. Dunn created AccelGraphics by orchestrating a spin out from Kubota Graphics. He built the company into a rapidly growing enterprise (the 8th fastest growing Silicon Valley public company in 1997). The company was subsequently sold to Evans and Sutherland.
Mr. Dunn has also held executive positions with Evans and Sutherland, Cygnet Systems, Avnet and Xerox. Mr. Dunn holds a BA degree from Colgate University and earned an MBA from Babson College.
An Advanced Approach to Surgical Management of SI Joint Dysfunction
Up to 25% of all low back pain is SI Joint in origin – but the diagnosis of SI Joint disease is frequently overlooked. (Cohen, et al.)
It is common to link low back pain with protruding disc even when neurological signs are absent. (Weksler, et al.)
It is common for pain from SI Joint dysfunction to mimic discogenic or radicular low back pain. (Weksler, et al.)
Many patients go on to receive lumbar fusion instead of SI Joint fusion – so SI Joint disease should be strongly considered in differential diagnosis of low back pain. (Weksler, et al.)
Now there is an approach to surgical management of SI Joint dysfunction that’s easier and less invasive than traditional open surgery.
The iFuse Implant System consists of porous plasma spray coated implants, surgically inserted across the SI Joint to create fixation leading to fusion—from the inside.
The iFuse creates a biomechanically rigorous fixation/fusion system, designed to support reliable fixation/fusion and acute weight bearing capacity.
With the iFuse Implant System, there is no need for BMP in conjunction with autologous bone graft or additional pedicle screws, rods or hollow modular anchorage screws or cannulated compression screws or threaded cages within the joint or fracture fixation screws.
iFuse benefits:
- Less invasive than traditional open surgery with no extensive soft tissue stripping
- straightforward surgical approach
- implant profile and design minimizes rotation and micromotion
- rigid titanium implants provide immediate post-op si Joint stability
- porous plasma spray coating with irregular surface designed to support stable bone fixation/fusion
- Larger implant surface area designed to maximize post-surgical weight bearing capacity
- biomechanically rigorous implant designed specifically to stabilize the heavily loaded si Joint
The iFuse Implant System is designed to be the sacroiliac joint fusion/fixation method of choice for spine surgeons.
iFuse is a minimally invasive surgical solution to replace open surgical SI Joint fusion.
With iFuse there's minimal incision size, minimal soft tissue stripping, minimal tendon irritation and reduced risk of infection.
iFuse is a simplified minimally invasive surgical procedure.
Just drill, broach, insert Implants and close.
iFuse has a simple technique which reduces OR time to less than 1 hour.
iFuse has 3X shear and 7X bending strength compared with screws.
iFuse has improved patient perception of stability post-implant.
The incidence of SI joint degeneration in patients was 75% at 5 years post-fusion, which was significantly higher than in the non-fusion group, 38.2%. (Ha, et al.)
Among patients with one-segment fusion, 91% developed SI joint degeneration. (Ha, et al.)
Regardless of whether the fusion includes the sacrum, the SI joint is influenced by increased mechanical stress arising from lumbar/lumbosacral fusion. (Ha, et al.)
Posterolateral lumbar/lumbosacral fusion can be a cause of SIJ degeneration. (Ha, et al.)
